# Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada

> **NCT04398147** · PHASE1,PHASE2 · UNKNOWN · sponsor: **CanSino Biologics Inc.** · enrollment: 696 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04398147
- **Lead sponsor:** CanSino Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2021-12-20
- **Final completion:** 2021-12-30
- **Target enrollment:** 696 (ESTIMATED)
- **Last updated:** 2020-07-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04398147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04398147, "Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04398147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*